What Is Pharmacogenomics?

Pharmacogenomics (PGx) is the study of how your genes affect your response to medications (Weinshilboum & Wang, 2004). It's one of the most practical and clinically actionable applications of genetic testing, with the potential to prevent dangerous adverse drug reactions and avoid ineffective treatments (Relling & Klein, 2011).

Why Does the Same Drug Work Differently for Different People?

You've probably noticed that medications affect people differently. Your friend might get relief from a standard dose of ibuprofen, while you need twice as much. Someone else might experience severe side effects from a medication you tolerate perfectly.

The answer lies in your DNA. A simple example: your genetics determine whether you're a fast or slow caffeine metabolizer, which is why some people can drink espresso at midnight and sleep fine while others feel wired after a single cup.

Your genes encode the enzymes that metabolize drugs. Genetic variations in these enzymes can significantly alter drug metabolism, leading to one of four phenotypes (Ingelman-Sundberg et al., 2007):

• Poor metabolizer - drugs stay in your system longer, increasing risk of side effects
• Intermediate metabolizer - reduced enzyme activity
• Normal (extensive) metabolizer - drugs work as expected
• Rapid/ultra-rapid metabolizer - drugs clear too quickly, potentially reducing effectiveness or causing toxicity with prodrugs

Key Genes in Pharmacogenomics

CYP2D6

This gene encodes an enzyme that metabolizes approximately 20-25% of all clinically used medications (Zhou et al., 2008), including:

• Codeine and tramadol (opioid analgesics)
• Tamoxifen (breast cancer treatment)
• Many antidepressants (SSRIs, tricyclics)
• Beta-blockers (cardiovascular conditions)

Population frequencies vary significantly:

• Poor metabolizers: ~5-10% of Caucasians, ~1-2% of Asians (Bradford, 2002; NCBI, 2025)
• Ultra-rapid metabolizers: ~1-2% of Caucasians, up to ~29% of Ethiopians (Akillilu et al., 1996)

This variability has serious clinical consequences. Poor metabolizers receive minimal pain relief from codeine because they cannot convert it to its active form, morphine (Crews et al., 2012).

CYP2C19

Critical for metabolizing:

• Clopidogrel (Plavix) - antiplatelet medication
• Proton pump inhibitors (omeprazole, Prilosec)
• Some antidepressants and antiepileptics

Population frequencies (Lee et al., 2020; Goldstein, 2001):

• Poor metabolizers: ~2-5% of Caucasians, ~13-23% of East Asians

SLCO1B1

This gene affects statin metabolism. Specific variants (particularly 521T>C) significantly increase the risk of statin-induced myopathy and rhabdomyolysis (Link et al., 2008).

Real-World Impact

Case: Codeine and CYP2D6

In 2013, the U.S. Food and Drug Administration (FDA) added a boxed warning to codeine after several pediatric deaths from respiratory depression (FDA, 2013). These children were ultra-rapid metabolizers - they converted codeine to morphine so rapidly that toxic levels accumulated, leading to fatal respiratory depression.

A simple pharmacogenomic test could have identified these high-risk patients and prevented these tragedies (Crews et al., 2012).

Case: Clopidogrel and CYP2C19

Clopidogrel (Plavix) is a prodrug prescribed to prevent blood clots after myocardial infarction or stent placement. It requires CYP2C19-mediated activation to become therapeutically effective (Mega et al., 2009).

Poor metabolizers achieve minimal active metabolite levels and therefore reduced antiplatelet effects. Multiple studies demonstrate that CYP2C19 poor metabolizers experience significantly higher rates of major adverse cardiovascular events (Sibbing et al., 2009; Shuldiner et al., 2009).

Current guidelines recommend alternative antiplatelet agents (prasugrel or ticagrelor) for poor metabolizers undergoing percutaneous coronary intervention (Scott et al., 2011).

How to Get Your Pharmacogenomics Report

If you have raw genetic data from direct-to-consumer testing services, you already have the data needed for pharmacogenomics analysis. GenomeInsight analyzes 14 key pharmacogenes and provides actionable, evidence-based insights for 50+ medications - all processed privately in your browser.

The Future of Medicine

The FDA currently includes pharmacogenomic information on over 200 drug labels (FDA, 2024). Major medical centers are increasingly implementing preemptive pharmacogenomic testing programs to guide prescribing decisions (Dunnenberger et al., 2015).

Within the next decade, checking genetic compatibility before initiating therapy will likely become as routine as checking for drug allergies (Relling & Evans, 2015).

---

Explore Your Own Genetics

Upload your raw DNA data to Genome Insight and get instant, research-backed insights into your health risks, drug metabolism, traits, and ancestry - completely free.

Upload your DNA data →

References

Akillilu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., & Ingelman-Sundberg, M. (1996). Environmental and genetic factors influencing CYP2D6 activity in Ethiopian healthy volunteers. European Journal of Clinical Pharmacology, 50(4), 321–326. https://doi.org/10.1007/s002280050103

Bradford, L. D. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 3(2), 229–243. https://doi.org/10.1517/14622416.3.2.229

Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shenkman, E. A., Callaghan, J. T., Sadhasivam, S., & Prows, C. A. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clinical Pharmacology & Therapeutics, 91(2), 321–326. https://doi.org/10.1038/clpt.2011.287

Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015). Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. Annual Review of Pharmacology and Toxicology, 55, 89–106. https://doi.org/10.1146/annurev-pharmtox-010814-124835

Goldstein, J. A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology, 52(4), 349–355. https://doi.org/10.1046/j.0306-5251.2001.01499.x

Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & Therapeutics, 116(3), 496–526. https://doi.org/10.1016/j.pharmthera.2007.09.004

Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kirita, Y., Gaedigk, A., Klein, T. E., Caudle, K. E., & Johnson, J. A. (2020). Pharmacogenomics of CYP2C19 and clopidogrel: Evolution, refinement, and future considerations. Clinical Pharmacology & Therapeutics, 108(1), 100–111. https://doi.org/10.1002/cpt.1838

Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M., & Collins, R. (2008). SLCO1B1 variants and statin-induced myopathy - A genomewide study. New England Journal of Medicine, 359(8), 789–799. https://doi.org/10.1056/NEJMoa0801936

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., & Sabatine, M. S. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel. New England Journal of Medicine, 360(4), 354–362. https://doi.org/10.1056/NEJMoa0809171

National Center for Biotechnology Information. (2025). CYP2D6 overview: Allele and phenotype frequencies. NCBI Medical Genetics Summaries. https://www.ncbi.nlm.nih.gov/books/NBK574601/

Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526(7573), 343–350. https://doi.org/10.1038/nature15817

Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464–467. https://doi.org/10.1038/clpt.2010.279

Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J. S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., & Johnson, J. A. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharmacology & Therapeutics, 94(3), 317–323. https://doi.org/10.1038/clpt.2013.105

Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., Damcott, C. M., Pakyz, R., Tantry, U. S., Gibson, Q., Pollin, T. I., Post, W., Parsa, A., Mitchell, B. D., Faraday, N., Herzog, W., & Gurbel, P. A. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302(8), 849–857. https://doi.org/10.1001/jama.2009.1232

Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dörrler, K., Morath, T., Schömig, K., von Beckerath, N., Seemann, F., Pogatsa-Murray, G., Floss, F., Wimmer, M., Kastrati, A., & Schömig, A. (2009). Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. European Heart Journal, 30(8), 916–922. https://doi.org/10.1093/eurheartj/ehp041

U.S. Food and Drug Administration. (2013). FDA drug safety communication: Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-threatening adverse events or death. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-codeine-use-certain-children-after-tonsillectomy-andor-adenoidectomy

U.S. Food and Drug Administration. (2024). Table of pharmacogenomic biomarkers in drug labeling. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling

Weinshilboum, R., & Wang, L. (2004). Pharmacogenomics: Bench to bedside. Nature Reviews Drug Discovery, 3(9), 739–748. https://doi.org/10.1038/nrd1497

Zhou, S. F. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism, 9(4), 310–322. https://doi.org/10.2174/138920008784220664

---

Related Reading

• How to Download Your 23andMe Raw Data - Get the file you need for pharmacogenomics analysis
• APOE4 and Alzheimer's Risk - Another critical health gene in your raw data
• MTHFR Gene Mutation - Folate metabolism and drug interactions
• Pharmacogenomics from 23andMe Data - Detailed guide to our 14-gene PGx analysis
• What You Can and Cannot Conclude - Important context for interpreting pharmacogenomics results

---

Related Reading

• pharmacogenomics implementation guide